Natera (NTRA) stock surged after reporting "blowout" Q2 results, driven by strong Signatera cancer test volume
An analyst noted "blowout volume" for Natera's Signatera cancer-detecting blood test in the second quarter, which saw 34,000 tests performed.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
US Hospital Sector Faces K-Shaped Path as Federal Cuts Loom, Financial Recovery Ends
-
2
An In-depth Analysis of the BitMEX Trading Platform and Perpetual Contracts: The Pioneer's Curtain Call and Market Evolution
-
3
OWL Token Value Analysis: Is Owlto Finance's Cross-Chain Bridge Token Worth Long-Term Attention?
-
4
Fed’s FIMA Repo Facility Went Unused for 8th Straight Week, suggesting Japan didn’t use the tool in its latest effort to support the yen
-
5
Exploring ICX and RSC: Analyzing Multiple Innovative Forces in the Blockchain World
-
6
APEX Coin Value Analysis: Distinguishing Investment Potential Between APEX Network and ApeX Protocol
-
7
AVN Coin Trading Guide: Avian Project Overview and Current Trading Channel Analysis
-
8
OpenAI is accelerating the development of its first consumer-grade smart speaker, with plans for a 2027 release and a price point of $300-400. Apple has filed a lawsuit alleging trade secret infringement.
-
9
EY-Parthenon expects the Fed to keep interest rates unchanged through year-end, citing a stable labor market despite Wall Street's payroll expectations.
-
10
EMIT Token Issuance Price and Time Machine NFTs Project Analysis: Market Status of Two Projects with the Same Name
Markets Today
Recommended Reading








